Bispebjerg Hospital

Running trials

• Not yet recruiting

  The MAB Trial: A Study of Tozorakimab to Reduce Lung Inflammation and Promote Lung Healing in People with COPD.

  2025-522359-24-00· Phase 2· University Of Leicester· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients

  NCT07581145· Phase 3· Ole Lander Svendsen· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

  NCT06892210· Phase 4· Copenhagen Respiratory Research· Source

• Recruiting

  Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC)

  NCT07460999· Zealand University Hospital· Source

• Recruiting

  The AIDPRO-CRC Trial

  NCT06645015· Zealand University Hospital· Source

• Recruiting

  A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures

  NCT06864130· Phase 4· Odense University Hospital· Source

• Recruiting

  A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

  NCT06642272· Phase 4· Herlev and Gentofte Hospital· Source

• Active, not recruiting

  A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· Phase 2· Eli Lilly and Company· Source

• Recruiting

  RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based

  NCT06614647· University of Aarhus· Source

• Recruiting

  Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload

  NCT06166654· Phase 3· Johannes Grand· Source

• Recruiting

  New treatments to reduce cardiovascular disease in type 1 diabetes

  2023-505794-32-04· Phase 3· Steno Diabetes Center Copenhagen· Source

• Recruiting

  Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of Tezepelumab

  NCT05507242· Phase 2· Region Hovedstaden· Source

• Active, not recruiting

  Metformin treatment of patients with hand osteoarthritis: A randomised, placebo-controlled trial

  2023-509181-38-00· Phase 3· Bispebjerg Hospital· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

  NCT06107426· AbbVie· Source

• Recruiting

  Coronary Computed Tomography Versus Invasive Angiography for Non-ST Elevation Acute Coronary Syndrome

  NCT06101862· Copenhagen University Hospital, Rigshospitalet· Source

• Recruiting

  The OPTIMIST study

  2023-505940-20-00· Phase 4· Aarhus University Hospital· Source

• Recruiting

  DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure

  NCT05276219· Phase 4· Copenhagen University Hospital, Rigshospitalet· Source

• Recruiting

  GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

  NCT06111105· Claus Lindbjerg Andersen· Source

• Recruiting

  DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies

  NCT06076811· University of Aarhus· Source

• Active, not recruiting

  Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

  NCT05696717· Phase 3· Theravance Biopharma· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

  NCT05630586· Phase 2· Aarhus University Hospital· Source

• Active, not recruiting

  The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

  NCT03129490· Phase 4· Herlev and Gentofte Hospital· Source

• Active, not recruiting

  DANNOAC- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study

  2022-501912-32-00· Phase 4· Bispebjerg Hospital· Source

• Enrolling by invitation

  Transcriptional Changes in Isolated Human Adipocytes During Obesity

  NCT06907212· University of Southern Denmark· Source

• Active, not recruiting

  The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

  NCT03129555· Phase 4· Herlev and Gentofte Hospital· Source

• Recruiting

  An European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and complications

  2022-501006-34-01· Phase 3· Odense University Hospital· Source

• Active, not recruiting

  IMPROVE-pT1: Accurate Allocation of Completion Resection in Early Colorectal Cancer

  NCT06040632· University of Aarhus· Source

• Recruiting

  The Organ Transplant Recipient HPV and Skin Cancer Study

  NCT05284877· Merete Haedersdal· Source

• Recruiting

  3TR Asthma Biologics Cohort (ABC) Study

  NCT06126692· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Active, not recruiting

  Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

  NCT05043103· Britannia Pharmaceuticals Ltd.· Source

• Recruiting

  Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

  NCT03127267· Phase 3· AB Science· Source

• Enrolling by invitation

  A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure

  NCT03984591· Phase 4· Bispebjerg Hospital· Source

• Active, not recruiting

  COMPuter-assisted Self-training to Improve EXecutive Function

  NCT04229056· Bispebjerg Hospital· Source

• Active, not recruiting

  ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial

  NCT04084249· Claus Lindbjerg Andersen· Source

• Recruiting

  Microstructure Imaging in Stroke Patients

  NCT04118790· Danish Research Centre for Magnetic Resonance· Source

• Active, not recruiting

  Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

  NCT03778554· Phase 4· Bispebjerg Hospital· Source

• Active, not recruiting

  IMPROVE: Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer

  NCT03637686· University of Aarhus· Source

• Active, not recruiting

  A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

  NCT03218488· Janssen-Cilag International NV· Source

• Active, not recruiting

  Medial Unicondylar Knee Arthroplasty vs Total Knee Arthroplasty

  NCT03396640· University Hospital, Gentofte, Copenhagen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer4 recruiting
• COPD4 recruiting
• Heart failure3 recruiting
• Osteoporosis2 recruiting
• Stroke2 recruiting
• Type 2 diabetes2 recruiting
• ALS (motor neurone disease)1 recruiting
• Asthma1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Diabetic foot ulcer1 recruiting
• Lung cancer1 recruiting
• Obesity1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  Incidence and Microbial Profiles of Periprosthetic Joint Infection After Total Knee Arthroplasty in Obese vs Non-Obese Patients

  NCT07398742· Bispebjerg Hospital· Source

• Completed

  Oxygen Targets in Acute Heart Failure With Pulmonary Congestion

  NCT05613218· Phase 2/3· Copenhagen University Hospital, Hvidovre· Source

• Completed

  Extending omalizumab treatment intervals in patients with chronic spontaneous urticaria (EXOTIC trial)

  NCT05916937· Phase 4· Bispebjerg Hospital· Source

• Completed

  Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

  NCT06020014· Phase 2· AstraZeneca· Source

• Completed

  A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.

  2022-502789-26-01· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)

  NCT05682859· Phase 4· Jacob Pontoppidan Thyssen· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Completed

  STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

  NCT05843578· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients.

  NCT05595681· Phase 1· Cell to Cure ApS· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

  NCT05518123· Phase 4· Pfizer· Source

• Completed

  A Study in Participants With Non-cirrhotic NASH With Fibrosis

  NCT05638737· Phase 2· AstraZeneca· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

  NCT05509400· Phase 4· Pfizer· Source

• Completed

  Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study

  NCT05330247· Bispebjerg Hospital· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  HIFU Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy

  NCT05119582· Joergen Serup· Source

• Completed

  Effects of Blood-flow Restricted Exercise Compared to Standard Rehabilitation in Patients With Knee Osteoarthritis

  NCT05437770· Bispebjerg Hospital· Source

• Completed

  A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice

  NCT05069545· Novo Nordisk A/S· Source

• Suspended

  A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)

  2024-516671-33-00· Phase 3· Ab Science· Source

• Completed

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· Phase 3· AstraZeneca· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source

• Completed

  Long-Term Evaluation of BIIB067 (Tofersen)

  NCT03070119· Phase 3· Biogen· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· University College Dublin· Source

• Completed

  Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism

  NCT01611896· Copenhagen University Hospital, Rigshospitalet· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Asthma53 works · 2 trials
• Osteoarthritis35 works · 3 trials
• Atopic dermatitis (eczema)24 works · 1 trial
• Hidradenitis suppurativa21 works · 1 trial
• Psoriasis18 works · 1 trial
• Psoriatic arthritis15 works · 0 trials
• Chronic spontaneous urticaria15 works · 1 trial
• Fibromyalgia5 works · 0 trials
• Multiple system atrophy5 works · 1 trial
• Giant cell arteritis4 works · 0 trials